EVAX (Evaxion Biotech AS) Gross-Profit-to-Asset % : 3.53% (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Evaxion Biotech AS Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Evaxion Biotech AS's annualized Gross Profit for the quarter that ended in Dec. 2024 was $0.49 Mil. Evaxion Biotech AS's average Total Assets over the quarter that ended in Dec. 2024 was $13.84 Mil. Therefore, Evaxion Biotech AS's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 was 3.53%.

Evaxion Biotech AS Gross-Profit-to-Asset % Historical Data

The historical data trend for Evaxion Biotech AS's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evaxion Biotech AS Gross-Profit-to-Asset % Chart

Evaxion Biotech AS Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

0.42

26.36

Evaxion Biotech AS Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															2.35	1.15	3.25	79.35	3.53

Competitive Comparison of Evaxion Biotech AS's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Evaxion Biotech AS's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Evaxion Biotech AS's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evaxion Biotech AS's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Evaxion Biotech AS's Gross-Profit-to-Asset % falls into.

Save Embed

;

Save Embed

;

Evaxion Biotech AS Gross-Profit-to-Asset % Calculation

Evaxion Biotech AS's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2024 )	/	( (Total Assets (A: Dec. 2023 )	+	Total Assets (A: Dec. 2024 ))	/ count )
	=	3.344	/	( (12.889	+	12.485)	/ 2 )
	=	3.344	/	12.687
	=	26.36 %

Evaxion Biotech AS's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2024 )	/	( (Total Assets (Q: Sep. 2024 )	+	Total Assets (Q: Dec. 2024 ))	/ count )
	=	0.488	/	( (15.185	+	12.485)	/ 2 )
	=	0.488	/	13.835
	=	3.53 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Evaxion Biotech AS Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Evaxion Biotech AS's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Evaxion Biotech AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evaxion Biotech AS (NAS:EVAX) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Dr. Neergaards Vej 5f, Hoersholm, DNK, 2970

Website

https://www.evaxion.ai

Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are: EVX-01, EVX-03, and EVX-02, which are vaccine candidates being developed for the treatment of various solid cancers. In addition, the company is developing EVX-B1, EVX-B2, EVX-B3, EVX-V1, and multiple other vaccine candidates for various infectious diseases, such as cytomegalovirus, N.gonorrhoeae, bacterial pathogens, and others.